Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
AZD5363 (Capivasertib) | Akt Inhibitor | CAS 1143532-39-1 | Selleck ...
AZD5363 - Potent AKT Inhibitor for Cancer Research | APExBIO
Capivasertib | AZD5363 | AKT inhibitor | TargetMol
AZD5363 - AKT Inhibitor | APExBIO
AZD5363 activates the phosphorylation of mTOR dependent on liver cancer ...
The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A ...
The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant ...
Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363 ...
AZD5363 treatment results in significant inhibition in PDGCX mouse ...
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide ...
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in ...
Frontiers | AZD5363 Inhibits Inflammatory Synergy between Interleukin ...
AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and ...
(PDF) The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant ...
AZD5363 inhibits prostate cancer tumor growth and induces cell-cycle ...
Effects of AZD5363 on IL-17 and insulin/IGF1 signaling pathways and ...
AZD5363 | AKT inhibitor | 1143532-39-1 | AdooQ®
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 ...
Apoptosis induction by AZD5363 and Compound E as a single and AZD5363 ...
Combination of AZD5363 with doxorubicin regulates key pro‐apoptotic ...
Figure 1. | Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates ...
Figure 1 from AKT Antagonist AZD5363 Influences Estrogen Receptor ...
AZD5363 | CAS:1143532-39-1 | Ark Pharma Scientific Limited
碧云天 AZD5363 (Akt抑制剂)(SF2820-5mg)_常规试剂、生化试剂_i实验室(iallab.com)-实验室试剂耗材仪器一站式服务！
AZD5363 (Capivasertib) | 卡帕塞替尼 | 购买Akt 抑制剂 - Selleck
NVP‐BEZ235 and AZD5363 modulate signaling pathways in a dose‐dependent ...
A combination of AZD5363 and FH5363 induces lethal autophagy in ...
Capivasertib | AZD5363 | AKT 抑制剂 | TargetMol
Combination of AZD5363 with doxorubicin induces apoptosis in ...
Capivasertib (AZD5363) is an Orally Active pan-AKT Kinase Inhibitor ...
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT ...
Akt抑制剂 | Akt Inhibitor
Oncology Letters
Capivasertib (AZD5363) | Akt Inhibitor | MedChemExpress
Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant ...
Capivasertib (AZD5363) | pan-AKT inhibitor | Probechem Biochemicals
Capivasertib (AZD5363) is an Orally Active and Potent Pan-AKT Kinase ...
Effects of the combination therapy with an AKT inhibitor (AZD5363) and ...
Efficacy of targeted AKT inhibition in genetically engineered mouse ...
Genetic alterations in the PI3K/AKT pathway and baseline AKT activity ...
Capivasertib (AZD5363) Akt Inhibitor | Selleck Chemicals | Mechanism ...
AKT1E17K‐mutated meningioma cell lines respond to treatment with the ...
AKT inhibitors | AKT activators | pathway | protein | function
美国APExBIO中文官网 - AZD5363|AKT inhibitor,pyrrolopyrimidine derived|CAS ...
3D and 2D binding pose interaction of AZD5363-AKT kinase complex in a ...
Inhibition of IGF-IR/InsR or PI3K abrogates AZD5363-induced AKT ...
Effects of pan-Akt inhibitor (AZD5363), MEK/ERK1/2 inhibitor (U0126 ...
(PDF) Preclinical Pharmacology of AZD5363, an Inhibitor of AKT ...
Combination treatment of prostate cancer with FGF receptor and AKT ...
A phase I dose-escalation study of enzalutamide in combination with the ...
Capivasertib (AZD5363) | Akt抑制剂 | MCE
International Journal of Oncology
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with ...
HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via ...
AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells - PMC
AbMole小课堂丨Capivasertib（AZD5363）：高选择性AKT抑制剂，作用机制及抗肿瘤研究应用 - 知乎
Combined treatments with AZD5363, AZD8542, curcumin or resveratrol ...
靶向降解AKT可以有效抑制肿瘤生长 - 知乎
Molecular characterization and cytotoxic effects of AZD5363, AZD8542 ...
AbMole小课堂丨Capivasertib（AZD5363）：泛AKT高效抑制剂，肿瘤研究的重要工具
Clonogenic analysis of the AZD5363+AZD8542+RV AZD5363+AZD8542+CCR and ...
APExBIO - AZD5363|AKT inhibitor,pyrrolopyrimidine derived|CAS# 1143532-39-1
AKT抑制剂AZD5363在制备治疗ARID1A缺陷型癌症药物中的应用
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors ...
